GHRH or analogues thereof for use in treatment of hepatic disease
The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH (1-44) -NH 2 , or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
1. A method for (i) preventing or delaying the onset of liver fibrosis or (ii) reducing liver fibrosis or the progression thereof, in a subject suffering from nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH), wherein said subject has a hepatic fat fraction (HFF) of at least about 10%, comprising administering an effective amount of trans-3-hexenoyl-GHRH (1-44) -NH 2 or a pharmaceutically acceptable salt thereof to said subject.
2. The method of claim 1 , wherein said subject has a hepatic fat fraction (HFF) of at least about 15%.
3. The method of claim 1 , wherein said subject has a hepatic fat fraction (HFF) of at least about 20%.
4. The method of claim 1 , wherein said subject has serum ALT levels of at least about 30 U/L.
5. The method of claim 1 , wherein said subject has serum ALT levels of at least about 35 U/L.
6. The method of claim 1 , wherein said subject has a NAFLD Activity Score (NAS) of at least 1 as measured by the NAS Clinical Research Network (NAS CRN) scoring system.
7. The method of claim 1 , wherein said subject has a NAFLD Activity Score (NAS) of at least 2 as measured by the NAS Clinical Research Network (NAS CRN) scoring system.
8. The method of claim 1 , wherein said subject has a NAFLD Activity Score (NAS) of at least 3 as measured by the NAS Clinical Research Network (NAS CRN) scoring system.
9. The method of claim 1 , wherein said subject has a NAFLD Activity Score (NAS) of at least 4 as measured by the NAS Clinical Research Network (NAS CRN) scoring system.
10. The method of claim 1 , wherein said subject has a reduction of hepatic fat fraction (HFF) by at least 4% (absolute reduction) following the treatment.
11. The method of claim 1 , wherein said subject has liver fibrosis.
12. The method of claim 11 , wherein said subject has a fibrosis score of at least 1C prior to the treatment.
13. The method of claim 11 , wherein said subject has a fibrosis score of at least 2 prior to the treatment.
14. The method of claim 1 , wherein said subject suffers from human immunodeficiency virus (HIV) infection.
15. The method claim 1 , wherein said subject has a body mass index (BMI) of at least about 25.
16. The method of claim 1 , wherein said pharmaceutically acceptable salt of trans-3-hexenoyl-GHRH (1-44) -NH 2 is an acetate salt.
17. The method of claim 1 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is administered by subcutaneous injection.
18. The method of claim 1 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is present in a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.
19. The method of claim 18 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition at a dose of about 1 mg/ml to about 10 mg/ml.
20. The method of claim 18 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition at a dose of about 1 mg/ml to about 8 mg/ml.
21. The method of claim 18 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition at a dose of about 4 mg/ml to about 8 mg/ml.
22. The method of claim 1 , wherein said trans-3-hexenoyl-GHRH (1-44) -NH 2 or pharmaceutically acceptable salt thereof is administered at a daily dose of about 1 mg to about 2 mg.